Age-Related Differences in Severe Adverse Events During Maintenance Therapy with PARP Inhibitors: A Retrospective Cohort Study in Japanese Patients with Ovarian Cancer

Targeted Oncology · Published 2026-02-21 · DOI 10.1007/s11523-026-01202-7

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1007/s11523-026-01202-7

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Cardiotoxicity Profiles of Osimertinib Compared with Other EGFR Tyrosine Kinase Inhibitors: A Real-World Comparative Incidence Analysis · Targeted Oncology · 2025 · Same journal
• MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies · Targeted Oncology · 2025 · Same journal
• Targeting DNA Damage Repair Pathways Beyond PARP Inhibition · Targeted Oncology · 2025 · Same journal
• Real-World Treatment Patterns in Advanced Cutaneous Melanoma in the USA · Targeted Oncology · 2026 · Same journal
• Bispecific Antibodies in Breast Cancer Immunotherapy: Mechanisms, Advances, and Translational Challenges · Targeted Oncology · 2026 · Same journal
• Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer · Targeted Oncology · 2026 · Same journal
• Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma? · Targeted Oncology · 2026 · Same journal
• Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study) · Targeted Oncology · 2026 · Same journal
• Weight-Based Pembrolizumab Dosing at 4 mg/kg Every 6 Weeks Leads to Exposures Below Approved Doses with Unestablished Efficacy: A Pharmacokinetic Model-Based Simulation Analysis · Targeted Oncology · 2025 · Same journal
• A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib’s Journey from Discovery to Approval and What’s Next in CDK Inhibition in Breast Cancer · Targeted Oncology · 2025 · Same journal